Poxel S.A.

Symbol: POXEL.PA




Market price today

  • -0.8066

    P/E Ratio

  • -0.0550

    PEG Ratio

  • 28.88M

    MRK Cap

  • 0.00%

    DIV Yield

Poxel S.A. (POXEL-PA) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.
Full-time employees:15
Address:Immeuble Le Sunway

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

General Outlook

When we look at how much money they make before expenses, they keep -8.024% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.342%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -13.247%. This tells us they're good at keeping money after all costs.

Return on Investments

Poxel S.A.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.253%.

Stock Prices

Poxel S.A.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.448, while its low point bottomed out at $0.42. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Poxel S.A.'s stock market.

Profitability Ratios

POXEL.PA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -1342.30% underscores its earnings before tax deductions. The effective tax rate stands at 1.31%, revealing its tax efficiency. The net income per EBT, 98.69%, and the EBT per EBIT, -3921.98%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 34.23%, we grasp its operational profitability.

Pretax Profit Margin-1342.30%
Effective Tax Rate1.31%
Net Income per EBT98.69%
EBT per EBIT-3921.98%
EBIT per Revenue34.23%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.29, and free cash flow per share, -0.29, depict cash generation on a per-share basis. The cash per share value, 0.07, showcases liquidity position. Lastly, the operating cash flow sales ratio, -4.65, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.29
Free Cash Flow per Share-0.29
Cash per Share0.07
Operating Cash Flow Sales Ratio-4.65
Free Cash Flow to Operating Cash Flow Ratio1.00

Debt and Leverage Ratios

An interest coverage of 0.22 indicates its ability to manage interest expenses.

Interest Coverage0.22

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 193.92%, indicates top-line expansion, while the gross profit growth, 98950.00%, reveals profitability trends. EBIT growth, 109.05%, and operating income growth, 109.05%, offer insights into operational profitability progression. The net income growth, 100.00%, showcases bottom-line expansion, and the EPS growth, 100.00%, measures the growth in earnings per share.

Revenue Growth193.92%
Gross Profit Growth98950.00%
EBIT Growth109.05%
Operating Income Growth109.05%
Net Income Growth100.00%
EPS Growth100.00%
EPS Diluted Growth100.00%
Weighted Average Shares Growth9.15%
Weighted Average Shares Diluted Growth9.15%
Operating Cash Flow Growth100.00%
Free Cash Flow Growth100.00%
5-Year Revenue Growth per Share-97.92%
3-Year Revenue Growth per Share-74.75%
10-Year Operating CF Growth per Share100.00%
5-Year Operating CF Growth per Share100.00%
3-Year Operating CF Growth per Share100.00%
10-Year Net Income Growth per Share100.00%
5-Year Net Income Growth per Share-100.00%
3-Year Net Income Growth per Share100.00%
10-Year Shareholders Equity Growth per Share100.00%
5-Year Shareholders Equity Growth per Share-100.00%
3-Year Shareholders Equity Growth per Share-100.00%
Receivables Growth-100.00%
Asset Growth-100.00%
Book Value per Share Growth100.00%
Debt Growth-100.00%
R&D Expense Growth-100.00%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -2,341,000, captures the company's total value, considering both debt and equity.

Enterprise Value-2,341,000
Average Receivables1,061,000
Average Payables1,469,000

Valuation Ratios

The price to sales ratio, 15.66, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -3.37, and price to operating cash flows, -2.30, gauge market valuation against cash flow metrics.

Price to Sales Ratio15.66
Price Cash Flow Ratio-2.30
Price Earnings to Growth Ratio-0.06
Enterprise Value Multiple1.90
Price to Operating Cash Flow Ratio-2.30
Price to Free Cash Flows Ratio-3.37
Enterprise Value to Sales-1.18
Enterprise Value Over EBITDA-1.18
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Poxel S.A. (POXEL.PA) on the EURONEXT in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.807 in 2024.

What is the ticker symbol of Poxel S.A. stock?

The ticker symbol of Poxel S.A. stock is POXEL.PA.

What is company IPO date?

IPO date of Poxel S.A. is 2015-02-06.

What is company current share price?

Current share price is 0.596 EUR.

What is stock market cap today?

The market cap of stock today is 28879398.000.

What is PEG ratio in 2024?

The current -0.055 is -0.055 in 2024.

What is the number of employees in 2024?

In 2024 the company has 15.